The new Medicare GLP-1 discount pilot promises a $50 monthly price for weight‑loss injections, yet a 68‑year‑old New Jersey resident discovered the relief comes with a catch.
Eligibility rules spark confusion
Jeff La Marca received a prescription for Zepbound in January, but the $750 price tag was beyond his reach. When the federal health program announced an 18‑month initiative that would subsidize three drugs for eligible enrollees, he applied, hoping the barrier would fall.
His request was denied. The denial notice gave no reason, but La Marca knows his diagnosis of severe obstructive sleep apnea places him among conditions that disqualify him from the $50 price.
Related: Medicare Cuts Cataract Payments Doctors Shift to Lasers
“I’m obese, morbidly obese, BMI 42. I had quadruple heart bypass surgery. I’m at risk for stroke. I’m prediabetic. And yet I can’t get it. I’m livid,” he said, echoing frustration felt by many who meet the weight criteria but carry other health issues.
The pilot covers Wegovy, the KwikPen version of Zepbound, and the oral agent Foundayo. To qualify, participants must have a Part D prescription plan, but the pre‑authorization request bypasses the insurer and goes to a contractor for the Centers for Medicare & Medicaid Services.
Beneficiaries with a body‑mass index of 35 or higher generally meet the weight threshold. Those with a BMI between 27 and 34 can still qualify if they have prediabetes or a cardiovascular condition.
However, the fine print limits the $50 price to users whose only indication is weight loss. Anyone whose condition—such as Type 2 diabetes or moderate to severe obstructive sleep apnea—is an FDA‑approved reason for the medication is sent back to their Part D plan, where copays can climb into the hundreds.
Related: Purina launches vet nutrition training for aging dogs
“The Bridge program was designed to target those people who can’t get coverage through Part D but would benefit from taking one for weight loss,” explained Juliette Cubanski, director of the Program on Medicare Policy at KFF.
Cost estimates vary. Cubanski projects that if 3.8 million people qualify and a quarter enroll for the full 18 months, the subsidy could total about $3.3 billion. A higher enrollment rate could push the figure toward $10 billion.
Cost implications for the federal budget
Early data show most prior‑authorization requests are processed within 12 hours, according to a CMS spokesperson. “This has allowed thousands of eligible beneficiaries to access the medications at pharmacies nationwide,” the official said.
